Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$1.20
▼ $0.04 (-3.2%)
Market data updated: 10/01 01:39 AM
News analyzed: 10/01/2026
Market Cap
$56.87M
Day Range
$1.20 - $1.25
52-Week Range
$0.62 - $8.01
Beta
—
Next Earnings
—
Support
$1.11
Resistance
$4.29
ZYBT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-54.2% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 2/13 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 200
Price is above the 200-day average
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 12.5% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
ZYBT’s investorScore of 47 reflects a mixed technical and risk profile, tempered by a strong news sentiment. The stock’s technical score of 29 is dragged down by conflicting signals: while it sits above its 200-day average—a bullish long-term indicator—it remains below the 50-day average, signaling short-term weakness. The negative MACD histogram and RSI of 37.4 (oversold %K at 0.0) suggest declining momentum, though the strong ADX (43.6) indicates a well-defined trend. Meanwhile, the risk score of 34 is heavily influenced by extreme volatility (ATR: 12.5%) and a historically disastrous Calmar ratio (-0.58), reflecting severe drawdowns and poor long-term returns. However, the news score of 100 stands out as an outlier, driven entirely by positive intraday observations—such as inclusion in top gainers/losers lists and pre-market activity—though these are transient and lack fundamental substance. The 74.2% 3-month outperformance relative to the index is notable but may be unsustainable given the underlying volatility and technical exhaustion.
The stock exhibits a split signal: above the 200-day average (bullish) but below the 50-day average (bearish), with negative MACD momentum and oversold RSI, despite a strong trend (ADX 43.6).
This divergence suggests potential short-term weakness despite long-term trend strength, which could lead to volatility or a pullback.
All news sentiment is positive, driven by intraday stock movement observations (e.g., pre-market activity, unusual volume), but lacks substantive fundamental or earnings-based context.
While intraday attention can drive short-term price action, it does not address underlying valuation or risk factors.
The stock demonstrates extreme volatility (ATR: 12.5%) and a historically poor Calmar ratio (-0.58), indicating severe drawdowns and a 3-year annualized return of -55.5%.
Such metrics highlight a high-risk profile, where past performance suggests potential for significant losses in volatile conditions.
StockIQ conclusion
ZYBT presents a moderate-risk profile with mixed technical signals, where short-term momentum appears exhausted despite long-term trend strength. The stock’s volatility and historical underperformance are major red flags, though its recent outperformance and intraday attention offer speculative opportunities. Without fundamental catalysts or reduced volatility, the risk-reward balance remains skewed toward caution. Investors should monitor for a breakout above key moving averages or substantive news to reassess the outlook.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
47
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
29
Risk
34
Sentiment
100
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Zhengye Biotechnology Holding Limited (ZYBT) has focused on its stock performance, particularly notable gains in trading sessions. On July 22, ZYBT shares surged 24% in the after-hours session, reaching $1.71, with a market cap of $135 million. The company was also among the pre-market gainers on July 23 alongside other biotech stocks, though no specific earnings or operational updates were highlighted. The headlines primarily reflect volatility and trading activity rather than substantive corporate developments.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Zhengye Biotechnology Holding Limited. News trend score: 100. Reason: 13 of the last 16 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
29
🎯 Conviction (vs. Emotion)
50
Psychology
32
Fundamentals
—
Technical
29
Valuation
—
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+86%
Market Narrative
53
Fundamental Reality
50
Narrative Gap
+3
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
👥 What the crowd believes
"ZYBT gained in pre-market (article 6) and after-market (article 9) sessions"
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 95/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect a clash between cyclical optimism and deep caution across methodologies. Samuel Armstrong Nelson’s near-perfect score highlights a favorable cycle position, suggesting the stock may be oversold and ripe for a rebound, while Jack Schwager and Charles Mackay also see disciplined setups with no crowd-driven mania. In contrast, Howard Marks (Market Cycle) leans toward early-to-mid cycle caution, and even Livermore’s neutral stance hints at a lack of clear momentum. Meanwhile, the majority—from Graham to Housel—struggle with insufficient data or outright red flags, with Marks, Loeb, and Housel flagging risk, volatility, or poor risk/valuation profiles. The divide underscores whether the stock’s technicals or cyclical appeal outweigh its murky fundamentals and speculative risks.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 95
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 76
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 70
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 67
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 51
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 38
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 31
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 21
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 291 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 9 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 13 positive, 2 neutral, 1 negative out of the last 16 articles.
ChartMill · 23.7.2026
ChartMill · 23.7.2026
Benzinga · 23.7.2026
ChartMill · 23.7.2026
Benzinga · 23.7.2026
Benzinga · 23.7.2026
ChartMill · 22.7.2026
ChartMill · 22.7.2026
Benzinga · 22.7.2026
ChartMill · 22.7.2026
ChartMill · 22.7.2026
Benzinga · 22.7.2026
ChartMill · 22.7.2026
Benzinga · 22.7.2026
Benzinga · 22.7.2026
Benzinga · 22.7.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Zhengye Biotechnology Holding Limited (ZYBT) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for ZYBT specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
ZYBT's technical score is 29/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 200-day average; +74.2% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: ATR: 12.5% of price; Calmar: -0.58 (3y annualized return -55.5% / max drawdown 95.4%); Price is below the 50-day average.
StockIQ has no recorded dividend payment history for ZYBT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
137,172 shares short as of 2026-09-15 · vs. 173,858 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
50.7% of trading volume this week was short selling, vs. 30.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology